Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and ... ( Patch Formulation May Provide New O...)

Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions

Date:5/8/2008

Patch Formulation May Provide New Option for Clinicians Concerned About

Systemic Exposure When Using an Oral NSAID

TAMPA, Fla., May 8 /PRNewswire-FirstCall/ -- Alpharma Inc. (NYSE: ALO), a leading global specialty pharmaceutical company, announced today that two studies to be presented this week at the American Pain Society annual meeting demonstrate the efficacy, tolerability and positive pharmacokinetic profile of Alpharma Pharmaceuticals' FLECTOR(R) Patch (diclofenac epolamine topical patch) 1.3%, the first and only prescription anti-inflammatory pain relief patch in the United States. FLECTOR(R) Patch has been available since January in the United States for the topical treatment of acute pain due to minor strains, sprains and contusions.

Results of one study, to be presented Friday, May 9, show that FLECTOR(R) Patch offered greater pain reduction and resolution of pain versus placebo patch. Results of another study, to be presented Thursday, May 8, demonstrate that the systemic exposure to diclofenac, or amount of active drug circulating in the bloodstream, with FLECTOR(R) Patch used topically every 12 hours over a period of four days was approximately 1 percent of a single 50-mg oral dose of the non-steroidal anti-inflammatory drug (NSAID) Voltaren(R) (diclofenac sodium enteric-coated tablets).

"Many physicians and patients would prefer a targeted approach to treating pain at the site of an injury, for a number of reasons," said Joseph W. Stauffer, D.O., Chief Medical Officer, Senior Vice President, Clinical Research and Medical Affairs, Alpharma Pharmaceuticals. "In addition to supporting the effectiveness of FLECTOR(R) Patch in reducing pain, these data confirm that the targeted delivery of FLE
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
2. Genetic Immunity Announces Data Related to the DermaVir Nanomedicine Patch in the Journal of Immunology
3. Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch
4. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
5. Genetic Immunity Presents Clinical Data on DermaVir Patch Immune Therapy at 15th Annual Conference on Retroviruses and Opportunistic Infections
6. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch
9. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report

Post Your Comments:

Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and ...( Patch Formulation May Provide New O...),Health